Myeloid transcriptome signature predicts disease progression. (A) Gene expression profiling of isolated bone marrow (BM) cells, CD14⁺ monocytes (CD14), osteoclasts (OCs), mesenchymal stromal cells (MSCs), osteoblasts (OBs), T cells (CD3), hematopoietic stem cells (CD34), memory B cells (MBCs), in vitro–generated polyclonal plasmablastic cells (PPCs), BM plasma cells (BMPCs), and CD138⁺ cells from patients with MGUS, asymptomatic MM (AMM), MM, and relapsed MM (rMM). Blue represents the absence of expression; red represents expression according to the presence-absence calls with negative probesets algorithm. Data represented by box and whisker plots. (B) Relationship between expression of AXL and CD138⁺CD38⁺ determined by flow cytometry for plasma cells isolated from patients with MGUS, MM, and rMM. (C) AXL nearest-neighbor analysis of CD138⁺ plasma cells in healthy controls (HC; green) and patients with MM (brown) from the Mayo Clinic microarray data set. Heatmap of 20 genes coexpressed with AXL in HC compared with MM (top) and the χ² test of the association of AXL expression in HC vs MM (bottom). (D) AXL nearest-neighbor analysis of CD138⁺ plasma cells in MGUS (orange) and MM (brown) from Mayo clinic microarray data set. Heatmap of 20 genes coexpressed with AXL in MGUS compared with MM (top) and the χ² test of the association of AXL expression in MGUS vs MM (bottom). (E) Kaplan-Meier analysis of dormancy signature genes and overall survival in the Millennium clinical trial microarray data set. (F) Univariate Cox regression analysis of the dormancy gene signature (red) and disease biomarkers. Forest plot of the HRs and 95% CIs (left) and summary table (right). (G) Cox-adjusted analysis of the dormancy gene signature (red) and disease biomarkers. Forest plot of the HRs and 95% CIs (left) and summary table (right).